Rosemont, Ill. — Should you be the victim of a snakebite, the best thing you can do is get to a hospital as quickly as possible, according to a new review article from the Journal of the American Academy of Orthopaedic Surgeons (JAAOS). Current me…
WINSTON-SALEM, N.C. — Thursday, Nov. 11, 2010 — Arsenic, a toxic compound with a reputation as a good tool for committing homicide, has a significant positive effect on the survival of patients with acute promyelocytic leukemia (APL), when admin…
Scientists at the Comprehensive Cancer Center of Wake Forest University have developed a colony of mice that successfully fight off virulent transplanted cancers. “The mice are healthy, cancer-free and have a normal life span,” the 10-member team reported in the Proceedings of the National Academy of Sciences online edition to be published the week of April 28. The transplantation of the cancer cells in these special mice provokes a massive infiltration of white blood cells that destroy the cancer, said Zheng Cui, M.D., Ph.D., associate professor of pathology at Wake Forest University Baptist Medical Center and the lead scientist.
The timing of treatment may be a key factor in whether hormone replacement therapy (HRT) can slow heart vessel disease, report researchers from Wake Forest University Baptist Medical Center and Tufts-New England Medical Center in the winter issue of Menopausal Medicine.
Injections of a progesterone-type hormone may be able to prevent more than a third of pre-term births in women with a history of giving birth early, reported Paul J. Meis, M.D., of Wake Forest University Baptist Medical Center, today (Feb. 6) at the Annual Meeting of the Society for Maternal-Fetal Medicine in San Francisco. “The evidence of this treatment’s effectiveness was so dramatic, the research was stopped early,” said Meis, the national principal investigator and a professor of obstetrics and gynecology at Wake Forest. “This drug is readily available and can be used by doctors to improve outcomes for mothers and babies.”
Researchers report that surgery combined with inserting heated chemotherapy drugs directly into the abdomen can improve survival rates in patients with disseminated cancer of the abdominal cavity.
Patients participating in the research study had a median overall survival of 16 months. Traditionally, patients with this condition, known as peritoneal carcinomatosis, survive only 3-6 months without treatment. Peritoneal cancer is the most common cause of death in patients with intra-abdominal cancers. Surgery alone has proven to be ineffective, as have external beam radiation therapy, brachytherapy and systemic chemotherapy.